Is Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Phathom Pharmaceuticals, Inc. at current levels.
Voquezna is rewriting 30 years of PPI dominance, and the stock trades like the launch is failing while scripts say otherwise.
Where PHAT is headed
Picture the US acid suppression market in late 2027. For three decades, doctors handed out proton pump inhibitors like candy: omeprazole, esomeprazole, pantoprazole, all working on the same broken pharmacology that fails roughly a third of patients with persistent heartburn. Phathom's bet is that vonoprazan, the first potassium-competitive acid blocker available in the US, eats a meaningful slice of that ~$3B branded PPI residual and a chunk of the much larger symptomatic market. The numbers are already showing it: revenue more than doubled year-on-year, gross margin sits at 85%, and forward earnings estimates imply the company crosses into profitability inside 18 months.
Read the full Compass Direction on PHAT
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $11.87).
See the full PHAT analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Phathom Pharmaceuticals, Inc. at current levels. Voquezna is rewriting 30 years of PPI dominance, and the stock trades like the launch is failing while scripts say otherwise.
What is PHAT's Compass Score?
Phathom Pharmaceuticals, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for PHAT?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the PHAT page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.